Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Theraclion

Market Cap 49.86M 56.76M 45.94M 43.01M 80.58M 5.38B 81.94M 552M 214M 2.64B 213M 208M 9.17B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 57.71M 65.69M 53.18M 49.78M 93.27M 6.22B 94.84M 639M 247M 3.05B 247M 241M 10.61B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day+66.25%
3 months+66.25%
6 months+66.25%
Current year+66.25%
Current year 0.53
Extreme 0.532
0.53
1 year 0.53
Extreme 0.532
0.53
3 years 0
Extreme 0.0002
0.59
5 years 0
Extreme 0.0002
2.28
10 years 0
Extreme 0.0002
2.6
Manager TitleAgeSince
Chief Executive Officer - 23/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 31/01/2018
Director/Board Member - 12/02/2019
Director/Board Member - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+66.25%-.--% - - 54.3M
+1.15%-0.69%+17.28%-10.47% 172B
+0.06%-3.33%-21.73%+23.20% 143B
+0.44%-1.31%-8.85%-24.86% 126B
+2.86%-2.81%-55.45%-15.51% 65.89B
+1.25%-1.84%+15.44%-3.75% 49.45B
+0.06%-2.21%-25.84%-32.63% 44.05B
+0.14%-1.30%+9.08%+6.07% 35.72B
-0.29%-0.93%+4.19%+37.47% 35.18B
+5.08%+0.77%-10.46%-20.17% 27.58B
Average +7.29%-1.60%-8.48%-4.52% 77.68B
Weighted average by Cap. +0.55%-1.98%-7.27%-4.71%

Financials

2024 2025
Net sales 830K 945K 765K 716K 1.34M 89.52M 1.36M 9.19M 3.56M 43.92M 3.55M 3.47M 153M 652K 742K 601K 562K 1.05M 70.31M 1.07M 7.21M 2.79M 34.5M 2.79M 2.73M 120M
Net income -5.76M -6.55M -5.3M -4.97M -9.3M -621M -9.46M -63.7M -24.66M -305M -24.6M -24.07M -1.06B -5.69M -6.48M -5.24M -4.91M -9.2M -614M -9.35M -62.95M -24.37M -301M -24.31M -23.79M -1.05B
Net Debt 3.41M 3.88M 3.14M 2.94M 5.51M 368M 5.61M 37.74M 14.61M 180M 14.57M 14.26M 627M 7.85M 8.94M 7.24M 6.77M 12.69M 847M 12.9M 86.88M 33.63M 415M 33.55M 32.83M 1.44B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!